The HLA-B*15:02 polymorphism and Tegretol®-induced serious cutaneous reactions in epilepsy: An updated systematic review and meta-analysis

Revue Neurologique

Volumn 174, Issue 5, 2018, Pages 278-291

  Chouchi, M ^a,b   Kaabachi, W ^a   Tizaoui, K ^a   Daghfous, R ^c   Aidli, S E ^c   Hila, L ^a  

^a UNIVERSITY OF TUNIS EL MANAR   (Tunisia)

^b Institut National de Neurologie Tunisia   (Tunisia)

^c National Pharmacovigilance Center   (Tunisia)

Author keywords

Carbamazepine; Epilepsy; HLA B*15:02 polymorphism; Meta analysis; Serious cutaneous reactions

Indexed keywords

CARBAMAZEPINE; HLA B ANTIGEN; ANTICONVULSIVE AGENT;

ANTICONVULSANT THERAPY; COCHRANE LIBRARY; EMBASE; EPILEPSY; GENETIC ASSOCIATION; GENETIC POLYMORPHISM; GENETIC RISK; HAN CHINESE; HUMAN; MEDLINE; META ANALYSIS; REVIEW; SKIN MANIFESTATION; STEVENS JOHNSON SYNDROME; SYSTEMATIC REVIEW; TOXIC EPIDERMAL NECROLYSIS; COMPLICATION; DRUG ERUPTION; GENETICS;

ANTICONVULSANTS; CARBAMAZEPINE; DRUG ERUPTIONS; EPILEPSY; HLA-B ANTIGENS; HUMANS; POLYMORPHISM, GENETIC;

EID: 85045714228     PISSN: 00353787     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.neurol.2017.11.006     Document Type: Review

References (61)

1. Pearce, R.E., Lu, W., Wang, Y., Uetrecht, J.P., Correia, M.A., Leeder, J.S., Pathways of carbamazepine bioactivation in vitro. III. The role of human cytochrome P450 enzymes in the formation of 2,3-dihydroxycarbamazepine. Drug Metab Dispos 36:8 (2008), 1637–1649.
2. Brodie, M.J., Dichter, M.A., Established antiepileptic drugs. Seizure 6:3 (1997), 159–174.
3. Perucca, E., Hedges, A., Makki, K.A., Ruprah, M., Wilson, J.F., Richens, A., A comparative study of the relative enzyme inducing properties of anticonvulsant drugs in epileptic patients. Br J Clin Pharmacol 18:3 (1984), 401–410.
4. Yasuda, S.U., Zhang, L., Huang, S.M., The role of ethnicity in variability in response to drugs: focus on clinical pharmacology studies. Clin Pharmacol Ther 84:3 (2008), 417–423.
5. Aldaz, A., Ferriols, R., Aumente, D., Calvo, M.V., Farre, M.R., García, B., et al. Pharmacokinetic monitoring of antiepileptic drugs. Farm Hosp 35:6 (2010), 326–339.
6. Alomar, M.J., Factors affecting the development of adverse drug reactions (Review article). Saudi Pharm J 22:2 (2014), 83–94.
7. Hung, S.I., Chung, W.H., Liu, Z.S., Chen, C.H., Hsih, M.S., Hui, R.C., et al. Common risk allele in aromatic antiepileptic-drug induced Stevens–Johnson syndrome and toxic epidermal necrolysis in Han Chinese. Pharmacogenomics 11:3 (2010), 349–356.
8. Ganeva, M., Gancheva, T., Lazarova, R., Troeva, J., Baldaranov, I., Vassilev, I., et al. Carbamazepine induced drug reaction with eosinophilia and systemic symptoms (DRESS) syndrome: report of four cases and brief review. Int J Dermatol 47:8 (2008), 853–860.
9. Daly, A.K., Genetic polymorphisms affecting drug metabolism: recent advances and clinical aspects. Adv Pharmacol 63 (2012), 137–167.
10. Tangamornsuksan, W., Chaiyakunapruk, N., Somkrua, R., Lohitnavy, M., Tassaneeyakul, W., Relationship between the HLA-B*1502 allele and carbamazepine-induced Stevens–Johnson syndrome and toxic epidermal necrolysis: a systematic review and meta-analysis. JAMA Dermatol 149:9 (2013), 1025–1032.
11. Yip, V.L., Marson, A.G., Jorgensen, A.L., Pirmohamed, M., Alfirevic, A., HLA genotype and carbamazepine-induced cutaneous adverse drug reactions: a systematic review. Clin Pharmacol Ther 92:6 (2012), 757–765.
12. Grover, S., Kukreti, R., HLA alleles and hypersensitivity to carbamazepine: an updated systematic review with meta-analysis. Pharmacogenet Genomics 24:2 (2014), 94–112.
13. Woolf, B., On estimating the relation between blood group and disease. Ann Hum Genet 19:4 (1995), 251–253.
14. Higgins, J.P., Thompson, S.G., Deeks, J.J., Altman, D.G., Measuring inconsistency in meta-analyses. BMJ 327:7414 (2003), 557–560.
15. Begg, C.B., Berlin, J.A., Publication bias and dissemination of clinical research. J Natl Cancer Inst 81:2 (1989), 107–115.
16. Kashiwagi, M., Aihara, M., Takahashi, Y., Yamazaki, E., Yamane, Y., Song, Y., et al. Human leukocyte antigen genotypes in carbamazepine-induced severe cutaneous adverse drug response in Japanese patients. J Dermatol 35:10 (2008), 683–685.
17. Ikeda, H., Takahashi, Y., Yamazaki, E., Fujiwara, T., Kaniwa, N., Saito, Y., et al. HLA class I markers in Japanese patients with carbamazepine-induced cutaneous adverse reactions. Epilepsia 51:2 (2010), 297–300.
18. Nguyen, D.V., Chu, H.C., Nguyen, D.V., Phan, M.H., Craig, T., Baumgart, K., et al. HLA-B*1502 and carbamazepine-induced severe cutaneous adverse drug reactions in Vietnamese. Asia Pac Allergy 5:2 (2015), 68–77.
19. Alfirevic, A., Jorgensen, A.L., Williamson, P.R., Chadwick, D.W., Park, B.K., Pirmohamed, M., HLA-B locus in Caucasian patients with carbamazepine hypersensitivity. Pharmacogenomics 7:6 (2006), 813–818.
20. Pirmohamed, M., Lin, K., Chadwick, D., Park, B.K., TNFalpha promoter region gene polymorphisms in carbamazepine-hypersensitive patients. Neurology 56:7 (2001), 890–896.
21. Alfirevic, A., Mills, T., Harrington, P., Pinel, T., Sherwood, J., Jawaid, A., et al. Serious carbamazepine-induced hypersensitivity reactions associated with the HSP70 gene cluster. Pharmacogenet Genomics 16:4 (2006), 287–296.
22. Amstutz, U., Shear, N.H., Rieder, M.J., Hwang, S., Fung, V., Nakamura, H., et al. Recommendations for HLA-A*15:02 and HLA-A*31:01 genetic testing to reduce the risk of carbamazepine-induced hypersensitivity reactions. Epilepsia 55:4 (2014), 496–506.
23. McCormack, M., Alfirevic, A., Bourgeois, S., Farrell, J.J., Kasperavičiūtė D., Carrington, M., et al. HLAA*3101 and carbamazepine-induced hypersensitivity reactions in Europeans. N Engl J Med 364:12 (2011), 1134–1143.
24. Niihara, H., Kakamu, T., Fujita, Y., Kaneko, S., Morita, E., HLA-A31 strongly associates with carbamazepine-induced adverse drug reactions but not with carbamazepine-induced lymphocyte proliferation in a Japanese population. J Dermatol 39:7 (2012), 594–601.
25. Chung, W.H., Hung, S.I., Hong, H.S., Hsih, M.S., Yang, L.C., Ho, H.C., et al. Medical genetics: a marker for Stevens–Johnson syndrome. Nature, 428(6982), 2004, 486.
26. Shi, Y.W., Min, F.L., Qin, B., Zou, X., Liu, X.R., Gao, M.M., et al. Association between HLA and Stevens–Johnson syndrome induced by carbamazepine in Southern Han Chinese: genetic markers besides B*1502?. Basic Clin Pharmacol Toxicol 111:1 (2012), 58–564.
27. Neuman, M.G., Cohen, L., Nanau, R.M., Hwang, P.A., Genetic and immune predictors for hypersensitivity syndrome to antiepileptic drugs. Transl Res 159:5 (2012), 397–406.
28. Then, S.M., Rani, Z.Z., Raymond, A.A., Ratnaningrum, S., Jamal, R., Frequency of the HLA-B*1502 allele contributing to carbamazepine-induced hypersensitivity reactions in a cohort of Malaysian epilepsy patients. Asian Pac J Allergy Immunol 29:3 (2011), 290–293.
29. Locharernkul, C., Loplumlert, J., Limotai, C., Korkij, W., Desudchit, T., Tongkobpetch, S., et al. Carbamazepine and phenytoin induced StevensJohnson syndrome is associated with HLA-B*1502 allele in Thai population. Epilepsia 49:12 (2008), 2087–2091.
30. Sun, D., Yu, C.H., Liu, Z.S., He, X.L., Hu, J.S., Wu, G.F., et al. Association of HLA-B*1502 and *1511 allele with antiepileptic drug-induced Stevens–Johnson syndrome in central China. J Huazhong Univ Sci Technolog Med Sci 34:1 (2014), 146–150.
31. Kaniwa, N., Saito, Y., Aihara, M., Matsunaga, K., Tohkin, M., Kurose, K., et al. HLA-B*1511 is a risk factor for carbamazepine-induced Stevens–Johnson syndrome and toxic epidermal necrolysis in Japanese patients. Epilepsia 51:12 (2010), 2461–2465.
32. Chen, P., Lin, J.J., Lu, C.S., Ong, C.T., Hsieh, P.F., Yang, C.C., et al. Carbamazepine-induced toxic effects and HLAB*1502 screening in Taiwan. N Engl J Med 364:12 (2011), 1126–1133.
33. Cheung, Y.K., Cheng, S.H., Chan, E.J., Lo, S.V., Ng, M.H., Kwan, P., HLA-B alleles associated with severe cutaneous reactions to antiepileptic drugs in Han Chinese. Epilepsia 54:7 (2013), 1307–1314.
34. He, X.J., Jian, L.Y., He, X.L., Wu, Y., Xu, Y.Y., Sun, X.J., et al. Association between the HLA-B*15:02 allele and carbamazepine-induced Stevens–Johnson syndrome/toxic epidermal necrolysis in Han individuals of northeastern China. Pharmacol Rep 65:5 (2013), 1256–1262.
35. Wu, X.T., Hu, F.Y., An, D.M., Yan, B., Jiang, X., Kwan, P., et al. Association between carbamazepine-induced cutaneous adverse drug reactions and the HLA-B*1502 allele among patients in central China. Epilepsy Behav 19:3 (2010), 405–408.
36. Khor, A.H., Lim, K.S., Tan, C.T., Wong, S.M., Ng, C.C., HLA-B*15:02 association with carbamazepineinduced Stevens–Johnson syndrome and toxic epidermal necrolysis in an Indian population: a pooled-data analysis and meta-analysis. Epilepsia 55:11 (2014), e120–e124.
37. Toh, D.S., Tan, L.L., Aw, D.C., Pang, S.M., Lim, S.H., Thirumoorthy, T., et al. Building pharmacogenetics into a pharmacovigilance program in Singapore: using serious skin rash as a pilot study. Pharmacogenomics J 14:4 (2014), 316–321.
38. Tassaneeyakul, W., Tiamkao, S., Jantararoungtong, T., Chen, P., Lin, S.Y., Chen, W.H., et al. Association between HLA-B*1502 and carbamazepine-induced severe cutaneous adverse drug reactions in a Thai population. Epilepsia 51:5 (2010), 926–930.
39. He, X.J., Jian, L.Y., He, X.L., Tang, M., Wu, Y., Xu, Y.Y., et al. Association of ABCB1, CYP3A4, EPHX1, FAS, SCN1A, MICA, and BAG6 polymorphisms with the risk of carbamazepine-induced Stevens–Johnson syndrome/toxic epidermal necrolysis in Chinese Han patients with epilepsy. Epilepsia 55:8 (2014), 1301–1306.
40. Fricke-Galindo, I., Martínez-Juárez, I.E., Monroy-Jaramillo, N., Jung-Cook, H., Falfán-Valencia, R., OrtegaVázquez, A., et al. HLA-A*02:01:01/-B*35:01:01/-C*04:01:01 haplotype associated with lamotrigine-induced maculopapular exanthema in Mexican Mestizo patients. Pharmacogenomics 15:15 (2014), 1881–1891.
41. Li, L.J., Hu, F.Y., Wu, X.T., An, D.M., Yan, B., Zhou, D., Predictive markers for carbamazepine and lamotrigine-induced maculopapular exanthema in Han Chinese. Epilepsy Res 106:1–2 (2013), 296–300.
42. Kim, W.J., Lee, J.H., Yi, J., Cho, Y.J., Heo, K., Lee, S.H., et al. A nonsynonymous variation in MRP2/ABCC2 is associated with neurological adverse drug reactions of carbamazepine in patients with epilepsy. Pharmacogenet Genomics 20:4 (2010), 249–256.
43. Ueda, K., Ishitsu, T., Seo, T., Ueda, N., Murata, T., Hori, M., et al. Glutathione S-transferase M1 null genotype as a risk factor for carbamazepine-induced mild hepatotoxicity. Pharmacogenomics 8:5 (2007), 435–442.
44. Tamura, T., Aiso, K., Johnston, K.E., Black, L., Faught, E., Homocysteine, folate, vitamin B-12 and vitamin B-6 in patients receiving antiepileptic drug monotherapy. Epilepsy Res 40:1 (2000), 7–15.
45. Yoo, J.H., Hong, S.B., A common mutation in the methylenetetrahydrofolate reductase gene is a determinant of hyperhomocysteinemia in epileptic patients receiving anticonvulsants. Metabolism 48:8 (1999), 1047–1051.
46. Vilaseca, M.A., Monrós, E., Artuch, R., Colomé C., Farré C., Valls, C., et al. Comprehensive analysis of the association of SCN1A gene polymorphisms with the retention rate of carbamazepine following monotherapy for new-onset focal seizures in the Chinese Han population. Clin Exp Pharmacol Physiol 39:4 (2012), 379–384.
47. Coppola, G., Ingrosso, D., Operto, F.F., Signoriello, G., Lattanzio, F., Barone, E., et al. Role of folic acid depletion on homocysteine serum level in children and adolescents with epilepsy and different MTHFR C677T genotypes. Seizure 21:5 (2012), 340–343.
48. Zhou, B.T., Zhou, Q.H., Yin, J.Y., Li, G.L., Qu, J., Xu, X.J., et al. Effects of SCN1A and GABA receptor genetic polymorphisms on carbamazepine tolerability and efficacy in Chinese patients with partial seizures: 2-year longitudinal clinical follow-up. CNS Neurosci Ther 18:7 (2012), 566–572.
49. Zhou, B.T., Zhou, Q.H., Yin, J.Y., Li, G.L., Xu, X.J., Qu, J., et al. Comprehensive analysis of the association of SCN1A gene polymorphisms with the retention rate of carbamazepine following monotherapy for new-onset focal seizures in the Chinese Han population. Clin Exp Pharmacol Physiol 39:4 (2012), 379–384.
50. Mawson, A.R., Eriator, I., Karre, S., Stevens–Johnson syndrome and toxic epidermal necrolysis (SJS/TEN): could retinoids play a causative role?. Med Sci Monit 21 (2015), 133–143.
51. Franco, V., Perucca, E., The pharmacogenomics of epilepsy. Expert Rev Neurother 15:10 (2015), 1161–1170.
52. Cheng, C.Y., Su, S.C., Chen, C.H., Chen, W.L., Deng, S.T., Chung, W.H., HLA associations and clinical implications in T-cell mediated drug hypersensitivity reactions: an updated review. J Immunol Res, 2014, 2014, 565320.
53. Man, C.B., Kwan, P., Baum, L., Yu, E., Lau, K.M., Cheng, A.S., et al. Association between HLAB*1502 allele and antiepileptic drug-induced cutaneous reactions in Han Chinese. Epilepsia 48:5 (2007), 1015–1018.
54. Wang, Q., Zhou, J.Q., Zhou, L.M., Chen, Z.Y., Fang, Z.Y., Chen, S.D., et al. Association between HLA-B*1502 allele and carbamazepine-induced severe cutaneous adverse reactions in Han people of southern China mainland. Seizure 20:6 (2011), 446–448.
55. Mehta, T.Y., Prajapati, L.M., Mittal, B., Joshi, C.G., Sheth, J.J., Patel, D.B., et al. Association of HLA-B*1502 allele and carbamazepine-induced Stevens–Johnson syndrome among Indians. Indian J Dermatol Venereol Leprol 75:6 (2009), 579–582.
56. Hung, S.I., Chung, W.H., Jee, S.H., Chen, W.C., Chang, Y.T., Lee, W.R., et al. Genetic susceptibility to carbamazepine-induced cutaneous adverse drug reactions. Pharmacogenet Genomics 16:4 (2006), 297–306.
57. Yip, V.L., Alfirevic, A., Pirmohamed, M., Genetics of immune-mediated adverse drug reactions: a comprehensive and clinical review. Clin Rev Allergy Immunol 48:2–3 (2015), 165–175.
58. Payne, P.W., Ancestry-based pharmacogenomics, adverse reactions and carbamazepine: is the FDA warning correct?. Pharmacogenomics J 14:5 (2014), 473–480.
59. Leckband, S.G., Kelsoe, J.R., Dunnenberger, H.M., George, A.L. Jr., Tran, E., Berger, R., et al. Clinical Pharmacogenetics Implementation Consortium guidelines for HLA-B genotype and carbamazepine dosing. Clin Pharmacol Ther 94:3 (2013), 324–328.
60. Ferrell, P.B. Jr., McLeod, H.L., Carbamazepine, HLA-B*1502 and risk of Stevens–Johnson syndrome and toxic epidermal necrolysis: US FDA recommendations. Pharmacogenomics 9:10 (2008), 1543–1546.
61. Locharernkul, C., Shotelersuk, V., Hirankarn, N., HLA-B* 1502 screening: time to clinical practice. Epilepsia 51:5 (2010), 936–938.